Too many hits in HIT?

American Journal of Hematology

Volumn 82, Issue 12, 2007, Pages 1035-1036

  Greinacher, Andreas ^a,b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DANAPAROID; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEPIRUDIN;

BLEEDING; DIAGNOSTIC PROCEDURE; EDITORIAL; ENZYME IMMUNOASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABORATORY TEST; MEDICAL DECISION MAKING; OPTICAL DENSITY; PATIENT CARE; PRIORITY JOURNAL; SCORING SYSTEM;

AUTOANTIBODIES; HEPARIN; HUMANS; PLATELET ACTIVATING FACTOR; THROMBOCYTOPENIA;

EID: 36748998833     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21047     Document Type: Editorial

References (14)

1. Eichler P, Raschke R, Lubenow N, et al. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002;116:887-891.
2. Lo G, Sigouin CS, Warkentin TE. What is the potential of overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007, in press.
3. Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994;34:381-385.
4. Warkentin TE, Sheppard JA, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? J Lab Clin Med 2005;146:341-346.
5. Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006;76:420-426.
6. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: A prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost, in press.
7. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - Results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005;3:2428-2436.
8. Lubenow N, Eichler P, Greinacher A. Results of a large drug-monitoring program confirming the safety and efficacy of lepirudin in patients with immune-mediated heparin-induced thrombocytopenia (HIT). Blood (Suppl I) 2002. Abstract.
9. Lubenow N, Eichler P, Lietz T, et al. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: An analysis of three prospective studies. Blood 2004;104:3072-3077.
10. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
11. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-1856.
12. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006;95:967-981.
13. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-765.
14. Warkentin TE, Greinacher A, editors. Heparin-induced Thrombocytopenia, 4th ed. New York: Informa Healthcare; 2007. 592 pp.